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The Role of Sinusoidal Endothelial
Cells in the Axis of Inflammation and
Cancer Within the Liver
Alex L. Wilkinson†, Maria Qurashi† and Shishir Shetty*
Centre for Liver and Gastrointestinal Research, Institute of Immunology and Immunotherapy, University of Birmingham,
Birmingham, United Kingdom
Liver sinusoidal endothelial cells (LSEC) form a unique barrier between the liver sinusoids
and the underlying parenchyma, and thus play a crucial role in maintaining metabolic
and immune homeostasis, as well as actively contributing to disease pathophysiology.
Whilst their endocytic and scavenging function is integral for nutrient exchange
and clearance of waste products, their capillarisation and dysfunction precedes
fibrogenesis. Furthermore, their ability to promote immune tolerance and recruit distinct
immunosuppressive leukocyte subsets can allow persistence of chronic viral infections
and facilitate tumour development. In this review, we present the immunological and
barrier functions of LSEC, along with their role in orchestrating fibrotic processes which
precede tumourigenesis. We also summarise the role of LSEC in modulating the tumour
microenvironment, and promoting development of a pre-metastatic niche, which can
drive formation of secondary liver tumours. Finally, we summarise closely inter-linked
disease pathways which collectively perpetuate pathogenesis, highlighting LSEC as
novel targets for therapeutic intervention.
Keywords: liver sinusoidal endothelial cell, capillarisation, endothelial dysfunction, inflammation, leukocyte
recruitment, fibrosis, hepatocellular carcinoma, metastasis
INTRODUCTION
Globally, liver disease is estimated to cause around two million deaths per year, and together,
cirrhosis and liver cancer account for 3.5% of all deaths worldwide (Rowe, 2017; Asrani et al.,
2019). As the fifth most common cancer and the second leading cause of all cancer-related deaths,
hepatocellular carcinoma (HCC) is becoming increasingly prevalent, and is associated with a
significant global health burden (Degasperi and Colombo, 2016; Bertuccio et al., 2017; Global
Burden of Disease Cancer Collaboration et al., 2017; Asrani et al., 2019). Chronic inflammation
plays a critical role in driving the development of HCC, as 90% of patients have an underlying
chronic liver disease (CLD) (O’Rourke et al., 2018). Moreover, the liver’s permissiveness to
metastasis and the hepatic tropism of many solid cancers makes the liver a frequent site of
secondary tumour deposits (Budczies et al., 2015; Mielgo and Schmid, 2020). Since metastasis
is responsible for up to 90% of all cancer-related deaths (Chaffer and Weinberg, 2011), better
understanding of the factors which permit growth of secondary malignancies is urgently needed. In
this review, we will discuss how the unique phenotype and function of liver sinusoidal endothelial
cells (LSEC) can contribute in diverse ways to the development of inflammation-induced primary
cancer and secondary tumours within the liver.
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Liver disease follows a common pathway of progression, from
inflammation to fibrosis and cirrhosis, independently of aetiology
(Schuppan and Afdhal, 2008; Pellicoro et al., 2014; Koyama and
Brenner, 2017). Initial liver injury, which can be toxin-induced,
viral, metabolic or autoimmune in origin, causes inflammation
which if unresolved can result in chronic hepatitis. Damage to
the hepatocytes and changes in the liver microenvironment lead
to fibrogenesis (aberrant wound healing and extracellular matrix
(ECM) deposition), which can distort the liver architecture and
impair liver function and regeneration (cirrhosis). Around 80–
90% of HCC cases arise on a background of cirrhosis (Davis
et al., 2008; O’Rourke et al., 2018) and, as such, risk factors
for HCC development include viral hepatitis, alcoholism and
obesity (Degasperi and Colombo, 2016; British Liver Trust, 2019).
Many patients are asymptomatic until their liver disease presents
at an advanced stage, due to the remarkable compensatory
capacity of the liver to fulfill its function even after suffering
extensive damage (Schuppan and Afdhal, 2008). Patients with
advanced disease have limited therapeutic options and the best
outcomes are seen in those patients who are able to undergo liver
transplantation. Yet, only 10% of the global transplant demands
are fulfilled by current rates (Asrani et al., 2019), thus, there is
a vast unmet clinical need to develop novel treatments for liver
disease patients.
The liver is strategically positioned to carry out its metabolic
and immunological function, since it receives 70–80% of its
blood supply from the gastrointestinal tract via the hepatic portal
vein, and the remainder from the hepatic artery (Mathew and
Venkatesh, 2018). The liver is exposed to countless microbial-
and food-derived antigens within the capillary beds of the liver,
referred to as the hepatic sinusoids. These vascular beds are
lined with specialised discontinuous endothelial cells, known
as LSEC, which not only form a unique barrier between the
bloodstream and the parenchyma, but also play an integral
role in liver physiology, immunology and pathophysiology
(Shetty et al., 2018).
An emerging role for LSEC in the development and
progression of both CLD and HCC has become evident
over the past few decades (Elvevold et al., 2008b; Sorensen
et al., 2015; Marrone et al., 2016; DeLeve and Maretti-Mira,
2017; Natarajan et al., 2017; Poisson et al., 2017; Shetty
et al., 2018; Hammoutene and Rautou, 2019). Furthermore,
the frequent growth of secondary tumours within the liver
often requires interactions with LSEC, contributing to a
metastatic niche which is exploited by numerous other cancer
types (Mielgo and Schmid, 2020). We discuss the role
of LSEC in disease pathogenesis and tumour development,




LSEC are the most abundant non-parenchymal cell type in
the liver, representing approximately 15–20% of liver cells
but only 3% of the total liver volume (Blouin et al., 1977;
Poisson et al., 2017; Shetty et al., 2018). Lying at the interface
between the systemic arterial and portal venous blood within the
sinusoids and the liver parenchyma, they form a unique barrier
between the circulation, and the underlying hepatocytes and
hepatic stellate cells (HSC) within the space of Disse (Sorensen
et al., 2015; Shetty et al., 2018). LSEC are highly specialised in
that they have minimal basement membrane and fenestrations,
arranged in sieve plates, rendering LSEC the most permeable
endothelial cells in the mammalian body (Braet and Wisse, 2002;
Poisson et al., 2017). Furthermore, LSEC are ideally positioned
to process and recycle blood-borne proteins and lipids both
from the gastrointestinal tract and the systemic circulation,
thus representing the most powerful scavenger system in the
body (Shetty et al., 2018). This is supported by the plethora of
endocytic and scavenger receptors expressed in LSEC (Sorensen
et al., 2015). Moreover, the atypical cell junctions between LSEC
and the low shear environment within the hepatic sinusoids
results in differences in leukocyte trafficking compared to the
conventional leukocyte adhesion cascade, which may yield
specific targets for recruitment during liver disease (Shetty et al.,
2008; Patten et al., 2019). It is these key features which distinguish
LSEC from other endothelia, allowing them to carry out their
homeostatic, filtration, endocytic (Figure 1) and immunological
functions (Figure 2).
Regulation of Hepatic Blood Flow
The liver sinusoids are characterised by low shear flow compared
to other capillary beds to maximise time for fluid and
solute exchange to occur (Poisson et al., 2017; Mathew and
Venkatesh, 2018). LSEC are key regulators of hepatic vascular
blood pressure via production of vasodilatory mediators in
response to shear stress (Figure 1). This effect is mediated
by activation of transcription factor Krüppel-like factor 2
(KFL2), resulting in release of nitric oxide (NO), via endothelial
nitric oxide synthase (eNOS) activity in LSEC (Shah et al.,
1997; Rockey and Chung, 1998; Parmar et al., 2006; Gracia-
Sancho et al., 2011). Simultaneously, shear stress downregulates
expression of vasoconstrictive factors, such as endothelin-
1 (ET-1), via KLF2 activation (Parmar et al., 2006). These
molecules act in a paracrine manner on HSC within the
space of Disse, maintaining their quiescent state and thus
inhibiting their vasoconstrictive effects (Kawada et al., 1993;
Deleve et al., 2008).
Whilst there is some suggestion that LSEC themselves may
mediate vascular flow by swelling to form inlet and outlet
sphincters (McCuskey, 1966, 2000), the most accepted concept is
that LSEC regulate blood flow indirectly via HSC (Rockey, 1997).
Hepatic stellate cells are contractile cells, expressing smooth
muscle proteins desmin and α smooth muscle actin (αSMA),
which enwrap the sinusoids and are ideally positioned to regulate
hepatic blood flow (Kawada et al., 1993; Rockey, 1997). As
such, LSEC remain in close proximity to HSC via interactions
between CXCR4 and CXCL12/stromal-derived factor 1α (SDF1α)
released by HSC, along with platelet-derived growth factor β
(PDGFβ)-PDGFRβ interactions. Alongside keeping LSEC and
HSC in close contact, this cell-cell communication is crucial
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FIGURE 1 | The role of LSEC in maintaining homeostasis and disease pathology following capillarisation and endothelial dysfunction. Left: LSEC have a distinct
morphology which facilitates their homeostatic function. (1) Lack of basement membrane and fenestrations arranged in sieve plates permit relatively free movement
of macromolecules, such as lipoproteins, towards hepatocytes within the parenchyma. Lipoproteins can also be endocytosed by scavenger receptors SR-B1 and
Stab1. (2) Scavenger receptors also facilitate uptake and clearance of waste products including apoptotic cell bodies (SCARF1), IgG immune complexes (CD32b),
lysosomal enzymes (MR), and collagen α chains (MR). (3) LSEC remain in close proximity with HSC within the space of Disse via CXCR4-SDF1α and PDGF-β
PDGFR-β interactions. (4) LSEC maintain HSC quiescence in response to shear stress through eNOS-dependent NO production, and inhibition of ET-1, via
transcription factor KFL2. (5) The differentiated LSEC phenotype maintains vasodilation of the sinusoids. (6) VEGF production by LSEC, HSC, hepatocytes and
cholangiocytes also maintain HSC quiescence and prevent LSEC capillarisation. Right: (1) Capillarisation is associated with upregulation of VCAM-1 and CD31, loss
of GATA4 signalling, reduced fenestrations, and basement membrane synthesis, leading to hyperlipoproteinaemia. This can be prevented by BMP9. (2) Endothelial
dysfunction is the inability to produce NO in response to shear stress, and paired with ET-1 synthesis, results in HSC activation. (3) Additional angiocrine signals
release from capillarised LSEC also perpetuate HSC activation, such as excess VEGF, Hh signals and TGFβ (4) Activated HSC begin to deposit ECM which
increases tissue stiffness, further stimulating HSC activation. (5) HSC respond by causing vasoconstriction which increases vascular resistance and shear stress.
(6) It is thought that LSEC respond to these mechanocrine signals via PIEZO channels, notch-dependent HEY1 and HES1 translocation and subsequent CXCL1
secretion. (7) This leads to neutrophil recruitment, and NETosis induces microvessel thrombosis which perpetuates increased vascular resistance resulting in portal
hypertension. (8) Ultimately, capillarisation and endothelial dysfunction precede angiogenesis and fibrosis, which increase the risk of cirrhosis and HCC. LSEC, liver
sinusoidal endothelial cells; SR-B1, scavenger receptor class B type 1; Stab1, stabilin-1; SCARF1, scavenger receptor class F member 1; CD32b, Fcγ receptor 2b;
MR, mannose receptor; RME, receptor-mediated endocytosis; HSC, hepatic stellate cell; CXCR4, C-X-C chemokine receptor type 4; SDF1α, stromal-derived factor
1α; PDGFβ platelet-derived growth factor β; eNOS, endothelial nitric oxide synthase; NO, nitric oxide; ET-1, endothelin-1; KLF2, Krüppel-like factor 2; VEGF, vascular
endothelial growth factor; VCAM-1, vascular cell adhesion molecule 1; BMP9, bone morphogenic protein 9; Hh, hedgehog; TGFβ, transforming growth factorβ ECM,
extracellular matrix; NETs, neutrophil extracellular traps; HCC, hepatocellular carcinoma.
for vascular tube maturation and integrity during angiogenesis
(Hellstrom et al., 1999).
Barrier Function and Endocytic
Properties
The discontinuous nature of the hepatic sinusoidal endothelia
permit relatively free trafficking of macromolecules between
the blood and the liver parenchyma (Figure 1). The fusion of
luminal and abluminal plasma membrane at sites other than
cell junctions form fenestrae with diameters of ∼50–150 nm
which, unlike other types of fenestrated endothelia, such as
those in the pancreas and adrenal glands, lack a diaphragm
(Wisse et al., 1985; Stan et al., 2012). Fenestral diaphragms are
comprised of plasmalemma vesicle-associated protein (PLVAP)
which is the only known molecular component of these
structures (Stan et al., 2004, 2012; Ioannidou et al., 2006;
Herrnberger et al., 2012). It is thought that PLVAP forms
homodimers arranged in radial fibrils, that are anchored
to the cell membrane, which regulate vascular permeability
by forming a size-selective sieve (Stan, 2004; Rantakari
et al., 2015). The role of PLVAP in regulating vascular
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FIGURE 2 | LSEC maintain immune tolerance and facilitate immune surveillance by several mechanisms. (1) Viral particles gain access to the parenchyma through
fenestrations and HBV/HCV can then go on to infect hepatocytes. (2) CD8+ T cells extend protrusions through fenestrations and can probe for viral antigens
presented by infected hepatocytes via MHCI. (3) LSEC can also take up viral particles via transcytosis, and RNA sensing by intracellular TLRs leads to production of
IFN-rich exosomes which inhibit viral replication. (4) LSEC express pathogen recognition receptors, including TLR4 and NOD1/2, which signal via NFκB leading to
cytokine production. (5) Clearance of dietary LPS via TLR4 induces tolerogenic responses by inhibiting NFκB translocation and antigen presentation.
(6) MR-mediated antigen uptake and presentation by MHCI induces tolerogenic CD8+ T cell responses in the presence of PDL1, which can be overcome by excess
TCR signalling in response to high antigen concentrations. (7) MR-mediated uptake also precedes antigen presentation to CD4+ T cells via MHCII, leading to Treg
induction in the presence of PDL1 and absence of co-stimulation. (8) Typically, classic adhesion molecules VCAM-1 and ICAM-1, as well as VAP-1, are involved in
Teff recruitment. VCAM-1 is often arranged in microdomains, forming endothelial adhesive platforms in associated with tetraspanin CD151. Hepatocytes can mediate
leukocyte recruitment indirectly by modulating expression of adhesion molecules. LSEC are also involved in recruitment of distinct leukocyte subsets via atypical
adhesion molecules and chemokines, such as (9) CD4+ and Treg cells by SCARF1 and Stab1, respectively, and (10) production of CXCL16 which promotes
retention of CXCR6+ NK and NKT cells. (11) LSEC also contribute to immune tolerance by inhibiting DCs and promoting apoptosis of CD4+ autoreactive thymic
emigrants. (12) LSEC recruit CXCR7+ BM SPCs via SDF1α, which mediate hepatocyte proliferation via HGF production and thus, liver regeneration. LSEC, liver
sinusoidal endothelial cells; HBV, hepatitis B virus; HCV, hepatitis C virus; TCR, T cell receptor; MHCI, major histocompatibility complex class I; TLR, toll-like receptor;
IFN, interferon; NOD, nucleotide-binding oligomerisation domain; NFκB, nuclear factor κ-light-chain-enhancer of activated B cells; LPS, lipopolysaccharide; MR,
mannose receptor; Ag, antigen; PD-1, programmed cell death protein 1; PDL1, programmed death ligand 1; Teff, effector T cell; IL-2, interleukin-2; MHCII, major
histocompatibility complex class II; Treg, regulatory T cell; VCAM-1, vascular cell adhesion molecule 1; ICAM-1, intercellular adhesion molecule-1; VAP-1, vascular
adhesion protein 1; Stab1, stabilin-1; SCARF1, scavenger receptor class F member 1; CXCL16, C-X-C chemokine ligand 16; CXCR6, C-X-C chemokine receptor 6;
NK, natural killer; NKT natural killer T; DC, dendritic cell; BM SPCs, bone marrow sinusoidal precursor cells; SDF1α, stromal-derived factor 1α; HGF, hepatocyte
growth factor; HSC, hepatic stellate cell.
homeostasis has been recently reviewed (Guo et al., 2016;
Bosma et al., 2018).
Despite a lack of PLVAP-containing diaphragms in adult
LSEC there is evidence to suggest that PLVAP plays a
critical role in development. Namely, it was recently shown
that PLVAP regulates the egress of foetal liver monocyte-
derived macrophages and subsequent seeding in the tissues,
since these cell populations were absent in tissues from
plvap-deficient mice (Rantakari et al., 2016). Furthermore,
PLVAP forms diaphragms in foetal LSEC and is present
during foetal angiogenesis in complex with lymphatic vessel
endothelial hyaluronan receptor 1 (LYVE-1), neuropilin-1
(NRP-1) and vascular endothelial growth factor receptor
2 (VEGFR2) (Rantakari et al., 2016; Auvinen et al., 2019).
Interestingly, Auvinen et al. (2019) also demonstrated PLVAP
expression in adult LSEC, which is the first report that
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clearly defines the expression of PLVAP independently of
fenestral diaphragms.
Early structural differentiation of the hepatic sinusoids occurs
in human embryos between 5 and 12 weeks of gestation,
during which time they downregulate continuous endothelial
markers CD31 and CD34 and gain sinusoidal markers CD32
and intercellular adhesion molecule 1 (ICAM-1) (Couvelard
et al., 1996; Poisson et al., 2017). Transcription factor GATA4
controls the distinct fenestrated phenotype which LSEC acquire
by 20 weeks of gestation (Geraud et al., 2017). Under steady state
conditions, fenestrated LSEC allow the passage of metabolites,
plasma proteins, lipoproteins and small chylomicron remnants
which are taken up by hepatocytes and HSC, whilst blood
cells including erythrocytes, leukocytes and platelets are retained
within the sinusoids (Poisson et al., 2017). The key role
for LSEC in lipid transfer is exemplified following loss of
fenestrations, where lipid uptake by hepatocytes is impaired and
hyperlipoproteinaemia ensues (Clark et al., 1988; Carpenter et al.,
2005; Hagberg et al., 2010; Herrnberger et al., 2014). Thus, LSEC
play an integral role in fluid and nutrient exchange and metabolic
homeostasis (Figure 1). Interestingly, fenestrations can also be
observed in tumour vasculature (Hashizume et al., 2000), which
may have implications for tumour persistence and progression,
as well as cancer cell invasion and metastasis.
Additionally, the expression of numerous endocytic and
scavenger receptors by LSEC permit their phenomenal endocytic
capacity which ranks the highest of all cells in the human
body (Smedsrod et al., 2009; Poisson et al., 2017). Fenestrations
are dynamic structures; they are frequently associated with
microtubules and actin filaments of the cytoskeleton, as well
as caveolae and clathrin-coated pits, which further facilitates
endocytic transport of material to and from the parenchyma
(Braet et al., 2009; Mönkemöller et al., 2015). The high endocytic
and lysosomal activity of LSEC means they are adept scavengers,
playing an important role in the clearance of waste products
from the circulation (Figure 1). They recognise and internalise
extracellular ligands which are trafficked through the endocytic
system and degraded. For instance, CD32b is the only Fcγ
receptor expressed by LSEC, which mediates the clearance of
small circulating IgG immune complexes (Lovdal et al., 2000;
Mousavi et al., 2007).
LSEC further contribute to lipid homeostasis via endocytic
uptake of high-density lipoproteins (HDLs) and oxidised or
acetylated low-density lipoproteins (LDLs), which is mediated
by scavenger receptor type B1 (SR-B1) and stabilin-1 (also
referred to as common lymphatic endothelial and vascular
endothelial receptor 1 (CLEVER-1) or fasciclin EGF-like,
laminin-type EGF-like, and link domain-containing scavenger
receptor-1 (FEEL-1) and stabilin-2, respectively (Krieger, 1999;
Li et al., 2011). Scavenger receptors also play a key role in
maintaining glycoprotein homeostasis (Lee et al., 2002), such as
clearance of advanced glycation end (AGE) products (Smedsrød
et al., 1997; Svistounov and Smedsrod, 2004). One example
is mannose receptor (MR), which binds numerous ligands
(Martinez-Pomares et al., 2001), including collagen α chains
(Malovic et al., 2007), tissue plasminogen activator (Rijken et al.,
1990; Martinez-Pomares, 2012) and lysosomal enzymes which
are utilised by LSEC (Elvevold et al., 2008a). LSEC are also
capable of taking up antigens, via MR-mediated endocytosis and
subsequent antigen presentation (Gazi and Martinez-Pomares,
2009; Martinez-Pomares, 2012; Zehner and Burgdorf, 2013),
highlighting that scavenger receptors also possess important
immunological functions (Figure 2).
IMMUNOLOGICAL ROLE OF LSEC
Recognition of Danger Signals and
Antigen Presentation
LSEC play an integral role in both innate and adaptive immunity
and contribute to maintenance of immune tolerance within
the liver (Figure 2) (Knolle and Wohlleber, 2016; Wohlleber
and Knolle, 2016). LSEC are responsible for the recognition
and clearance of microbial antigens and, as such, express
many pattern recognition receptors (PRRs) in addition to their
scavenger receptors. LSEC respond to stimulation of toll-like
receptors (TLR) 1-9 (Martin-Armas et al., 2006; Wu et al.,
2010), and constitutively express three protein components of the
inflammasome (Boaru et al., 2012) and intracellular nucleotide-
binding oligomerisation domain (NOD)-like receptors, including
NOD1 and NOD2, along with RIPK2 (Huang et al., 2018).
Lipopolysaccharide (LPS) is predominantly cleared by the
liver, specifically, 75% by LSEC and 25% by Kupffer cells
(KC) (Mathison and Ulevitch, 1979; Yao et al., 2016). LSEC
recognition of LPS is mediated by TLR4 and CD14, resulting in
activation of the myeloid differentiation primary response gene
88 (MyD88) pathway, nuclear translocation of nuclear factor-
κB (NF-κB), and production of pro-inflammatory mediators
including interleukin-6 (IL-6) and tumour necrosis factor α
(TNFα) (Hayashi et al., 2006; Wu et al., 2010; Faure-Dupuy
et al., 2018). However, LSEC responsiveness to LPS diminishes
following successive exposure, not due to TLR4 downregulation,
but rather a reduction in NFκB nuclear translocation (Uhrig et al.,
2005). This tolerogenic response reduced subsequent CD54-
mediated leukocyte adhesion, and is thought to represent a
mechanism by which LSEC prevent liver over-activation and
inflammation in response to low-level dietary LPS (Uhrig et al.,
2005). Furthermore, recognition of LPS promotes tolerance
induction by downregulating antigen-presentation by LSEC and
thus, T cell activation (Knolle et al., 1999).
LSEC also participate in viral clearance (Figure 2). It is
estimated that around 90% of the viral load during an infection
is cleared by LSEC, as has been shown for adenovirus and
human immunodeficiency virus (HIV)-like particles, with the
latter being cleared by the sinusoids at an astonishing rate of
100 million particles per minute (Ganesan et al., 2011; Mates
et al., 2017). Anderson and colleagues determined the rate of
clearance in mice following tail vein infusion with viral particles,
by periodic sampling of peripheral blood, and analysis of viral
load via quantitative PCR or ELISA over 30 min. Fluorescently
labeled viral particles were localised predominantly within LSEC,
as determined by fluorescent immunohistochemistry of murine
livers following viral infusion. A recent study utilised real-time
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deconvolution microscopy to show that LSEC contribute to
uptake and lysosomal degradation of enterobacterial viruses,
such as bacteriophage, acting as a primary anti-viral defense
mechanism (Oie et al., 2020). This has implications not only
for innate immune responses but also may contribute to the
low efficiency of phage therapy, since bacteriophages used for
gene delivery appear to be rapidly cleared from the circulation.
Furthermore, the morphology of LSEC facilitate immune
surveillance against hepatotropic viral infections. Specifically,
CD8+ T cells have been shown to extend protrusions through
LSEC fenestrae, probing for viral antigens presented by infected
hepatocytes (Warren et al., 2006; Guidotti et al., 2015).
Antigen uptake via LSEC scavenger receptors, followed by
antigen presentation, is a key step in promoting T cell tolerance
under physiological conditions (Figure 2). Mannose receptor-
mediated uptake, processing and presentation of antigen via
major histocompatibility complex (MHC) class I on LSEC
facilitates antigen cross-presentation to CD8+ T cells (Limmer
et al., 2000; Burgdorf et al., 2006, 2007), inducing tolerance
via upregulation of co-inhibitory molecule programmed cell
death ligand 1 (PD-L1) (Diehl et al., 2008). This has been
demonstrated for both oral (Limmer et al., 2005) and tumour
antigens (Berg et al., 2006; Höchst et al., 2012). LSEC can
also present antigen to CD4+ T cells via MHC class II, which
is constitutively expressed at low levels, but upregulated in
response to inflammatory stimuli (Lohse et al., 1996; Knolle
et al., 1998). However, the low expression of co-stimulatory
molecules in LSEC, particularly in the presence of IL-10, means
they are poor stimulators of naïve CD4+ T cell activation (Katz
et al., 2004), instead inducing development of regulatory T cells
(Treg) which suppress immune responses (Carambia et al., 2014).
Furthermore, LSEC can impair the ability of DCs to induce naïve
T cell proliferation in vitro, although the mechanism remains
unknown (Bertolino, 2008; Schildberg et al., 2008). LSEC also
induce tolerance of recent autoreactive CD4+ thymic emigrants,
who acquire IL-10-producing capacity and undergo higher rates
of apoptosis via enhanced FasL and Bim expression (Xu et al.,
2016). Together, these findings define a key role for LSEC in
maintaining peripheral tolerance (Figure 2).
Alternatively, LSEC can also present antigen to elicit
immunogenic T cell responses (Figure 2). For example, LSEC
TLR1/2 stimulation with palmitoyl-3-cysteine-serine-lysine-4
(P3C) induced activation of virus-specific CD8+ T cells via
low level IL-12 secretion in the absence of PD-L1 expression
(Liu et al., 2013). Furthermore, stimulation of NOD1, NOD2
and RIPK2 with diaminopimelic acid (DAP) promotes LSEC
maturation and HBV-specific T cell activation (Huang et al.,
2018). This effect was mediated by NFκB and mitogen-activated
protein kinase (MAPK) activation, and subsequent expression of
pro-inflammatory chemokines and cytokines, which ultimately
primed HBV-stimulated CD8+ T cells to increase their interferon
γ (IFNγ) and IL-2 production.
Equally, high antigen concentrations are sufficient to shift
a tolerogenic response to an immunogenic one via excess T
cell receptor (TCR) signalling (Schurich et al., 2010). Cross-talk
between helper CD4+ and CD8+ T cells is mediated by LSEC,
involving simultaneous T cell activation, cross-priming, IL-2
release, TCR stimulation and IL-6 signalling, which ultimately
enhances LSEC-primed CD8+ T cell effector (Teff) functions
(Böttcher et al., 2014; Wittlich et al., 2017). These findings
provide evidence that LSEC can switch their homeostatic
tolerogenic phenotype to an immunogenic one, promoting T
cell immunity in response to microbial antigens. Understanding
how LSEC mediate liver-specific tolerance and immunity will
have important implications when attempting to overcome
T cell tolerance, such as during chronic viral infection
or liver cancer.
Leukocyte Recruitment
LSEC also contribute to another important aspect of immunity,
namely the trafficking of leukocytes through recruitment from
the peripheral circulation into the liver (Figure 3). Leukocyte
recruitment follows a multi-step adhesion cascade involving
several receptor-ligand interactions, which enable capture
of circulating immune cells by activated endothelium, and
subsequent transmigration to tissue injury or infection sites (Ley
et al., 2007). This process is stimulated by recognition of pattern-
and danger-associated molecular patterns (PAMPs/DAMPs)
by liver immune sentinels, such as KCs, resulting in their
activation and subsequent release of cytokines and chemokines.
Generally, initial tethering is mediated by selectins and
subsequent rolling by integrin activation, which are dictated
by the “catch-bond” phenomenon, whereby receptor-ligand
interactions are strengthened under conditions of increased
shear stress (Marshall et al., 2003; Yago et al., 2007). This
brings about cell arrest, followed by intravascular crawling and
transmigration through the endothelium into the tissue sites.
Typical adhesion molecules involved in leukocyte recruitment
include ICAM-1 and vascular cell adhesion molecule 1
(VCAM-1), which form endothelial adhesive platforms by
establishing microdomains in association with tetraspanins
(Poisson et al., 2017). For instance, CD151 is a tetraspanin
which was shown to associate with LSEC VCAM-1 and mediate
lymphocyte adhesion under physiological flow conditions in vitro
(Wadkin et al., 2017).
In contrast to conventional vascular beds, the low shear
flow conditions within the hepatic sinusoids leads to lack of
selectin-dependent initial tethering and rolling, paving the way
for atypical adhesion molecules (i.e., scavenger receptors) to play
a more predominant role (Shetty et al., 2008). The involvement
of atypical adhesion molecules in leukocyte recruitment has
been previously reviewed (Patten and Shetty, 2018). Scavenger
receptors are involved in recruitment of distinct leukocyte
subsets, and as such, may prove to be novel liver-specific
therapeutic targets (Figure 3) (Patten et al., 2019). One example
is stabilin-1, which is highly expressed on LSEC in response
to hepatocyte growth factor (HGF) and, with the support of
adhesion molecules ICAM-1 and vascular adhesion protein
1 (VAP-1), permits the specific transmigration of Treg across
the sinusoidal endothelium (Shetty et al., 2011). In addition,
scavenger receptor class F, member 1 (SCARF1) mediates
selective CD4+ T cell adhesion (Patten et al., 2017a), alongside
its scavenging functions in the clearance of LDLs and apoptotic
bodies (Patten, 2018).
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FIGURE 3 | LSEC orchestrate the immune microenvironment during chronic inflammation. (1) During chronic inflammation, repeated hepatocyte injury results in
release of DAMPs which are sensed by KC, resulting in their activation and subsequent production of pro-inflammatory cytokines. These DAMPs also trigger
cytokine release from LSEC via NFκB and inflammasome signalling, further perpetuating LSEC and KC activation. This is exacerbated by endothelial dysfunction.
(2) Production of BMP4 by LSEC can also promote viral replication which can worsen hepatocyte damage during chronic viral infection. Activated LSEC (3) secrete
chemokines and (4) upregulate their expression of adhesion molecules, which facilitates leukocyte recruitment, adhesion and transmigration. (5) Leukocytes can be
retained within the space of Disse due to VAP-1 expression by HSC. (6) Following SCARF1-mediated adhesion, CD4+ T cells have been shown to perform lateral
intracellular crawling between LSEC, which is mediated by ICAM-1 and Stab1. LSEC are also important for recruiting distinct pro-inflammatory leukocyte subsets
during diseases states, including (7) gut-homing lymphocytes via α4β7-MAdCAM interactions, and (8) CD16+ Mo via secretion of CX3CL1. LSEC, liver sinusoidal
endothelial cells; DAMPs, danger-associated molecular patterns; KC, Kupffer cell; TNFα, tumour necrosis factor α; MCP-1, monocyte chemoattractant protein 1;
IL-6, interleukin-6; NFκB, nuclear factor κ-light-chain-enhancer of activated B cells; NLRP, nucleotide-binding oligomerisation domain, leucine-rich repeat and pyrin
domain; NO, nitric oxide; BMP4, bone morphogenic protein 4; ICAM-1, intercellular adhesion molecule-1; VAP-1, vascular adhesion protein 1; VCAM-1, vascular cell
adhesion molecule 1; SCARF1, scavenger receptor class F member 1; Stab1, stabilin-1; MAdCAM, mucosal addressin cell adhesion molecule 1; Mo, monocyte;
CX3CL1, fractalkine; HSC, hepatic stellate cell.
There is also an integral role for chemokines in leukocyte
recruitment (Figures 2, 3) (Oo et al., 2010). Chemokines
contribute to firm adhesion of leukocytes by binding to
G-protein coupled receptors and inducing conformational
changes in integrins to facilitate high affinity binding. It is
also thought that chemokines are involved in lymphocyte
compartmentalisation in liver diseases, with CXCR3 ligands
promoting parenchymal recruitment (Curbishley et al., 2005),
and CCR5 ligands contributing to recruitment to the portal
tracts (Shields et al., 1999; Ajuebor et al., 2004). CXCL9-11 are
important for T cell recruitment and transmigration following
endothelial activation with IFNγ and TNFα (Curbishley et al.,
2005). These chemokine ligands are produced by neighbouring
cells and can be transcytosed by LSEC and presented on
their cell surface (Middleton et al., 2002; Schrage et al.,
2008; Neumann et al., 2015). They can also be circulated
within the sinusoids and captured by proteoglycans within
the endothelial cell glycocalyx (Curbishley et al., 2005).
Fractalkine (CX3CL1) interacts with CX3CR1 on CD16+
monocytes to facilitate adhesion and transmigration in an
integrin- and VAP-1-dependent manner (Aspinall et al., 2010).
LSEC also express CXCL16 (Geissmann et al., 2005), which
interacts with CXCR6+ Teff cells to mediate recruitment
(Heydtmann et al., 2005; Sato et al., 2005), as well as natural
killer (NK) (Hudspeth et al., 2016; Stegmann et al., 2016) and
NKT cells (Geissmann et al., 2005) to promote migration
during immune surveillance. Thus, chemokines play an
important role in recruiting distinct leukocyte subsets across
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LSEC and maintaining the immune microenvironment
within the liver.
Hepatocyte paracrine factors can also enhance expression
of LSEC adhesion molecules including ICAM-1, VCAM-1
and VAP-1, indirectly regulating immune cell recruitment
(Edwards et al., 2005). LSEC adhesion molecules are relevant
in tumourigenesis and metastatic spread and their regulation
by transformed hepatocytes or metastatic deposits is of interest.
For instance, tetraspanin CD151 is upregulated on LSEC by
hepatoma-derived factors and collaborates with VCAM-1 to
facilitate recruitment (Wadkin et al., 2017). CD151 has been
shown to form endothelial adhesive platforms with VCAM-1 and
ICAM-1 in human umbilical vein endothelial cells (HUVEC),
permitting lymphocyte adhesion and transmigration, although
these structures are yet to be identified in LSEC (Barreiro
et al., 2005; Barreiro et al., 2008). Following transmigration,
there is also evidence to suggest hepatocytes can modulate
T cell populations by engulfment and subsequent lysosomal
degradation of autoreactive CD8+ T cells (Benseler et al., 2011)
and Treg (Davies et al., 2019). These cell-cell interactions have
been recently reviewed (Davies et al., 2020).
Although transmigration typically occurs via the paracellular
route between endothelial cell junctions, in the liver, lymphocytes
frequently extravasate through the endothelial cell body via
the transcellular route (Shetty et al., 2011; Patten et al.,
2017b). There have also been reports of lymphocyte intracellular
crawling within LSEC, shown by live confocal imaging, which
was mediated by IFNγ along with ICAM-1 and stabilin-
1 expression (Patten et al., 2017b). This demonstrates that
LSEC are not just a simple barrier but play an active role
in regulating the liver microenvironment. Indeed, the immune
microenvironment and leukocyte subsets within it determine
the fate of liver injury – resolution, or persistence and chronic
hepatitis. Furthermore, excessive immunosuppressive leukocyte
subsets promote pathogen escape and tumourigenesis.
LSEC PATHOPHYSIOLOGY
An expanding body of evidence strongly implicates LSEC in the
development of CLD, and thus liver cancer (Figure 4), due to the
nature of liver disease progression from fibrosis to cirrhosis and
HCC development (Figure 5). General disease pathways involve
chronic liver injury and subsequent endothelial and epithelial
damage and dysfunction, which leads to HSC activation, excess
ECM deposition, and fibrogenesis. This perpetuates liver damage
and can lead to cirrhosis if unresolved (Patten et al., 2019).
LSEC contribute to pathogenesis in several ways, by fostering
conditions which allow persistence of chronic viral infections and
driving processes which initiate and exacerbate fibrosis. These
include LSEC capillarisation, characterised by loss of fenestrated
morphology and acquisition of vascular phenotype, angiogenesis,
and endothelial-to-mesenchymal transition (EndMT). LSEC also
release endothelial-derived growth factors, known as angiocrine
factors, which determine the balance between regeneration and
fibrosis as well as orchestrating tumourigenesis.
Chronic Viral Infection
As discussed above, LSEC play an important role in viral
clearance (Figure 2), by direct sensing of viral RNA which can
lead to release of type I and III interferon-rich exosomes and
inhibition of viral replication (Pohlmann et al., 2003; Broering
et al., 2008; Giugliano et al., 2015). LSEC also recruit and position
Teff through expression of ICAM-1, VCAM-1 and VAP-1, and
presentation of CXCR3 ligands (Curbishley et al., 2005). They
also aid retention of CXCR6+ T cells via CXCL16 expression
(Heydtmann et al., 2005; Sato et al., 2005).
Conversely, LSEC can also promote hepatotropism of HBV
and HCV by permitting them access to the parenchyma,
through fenestrations and by transcytosis (Breiner et al., 2001;
Protzer et al., 2012). Hence, tolerogenic responses may help viral
evasion from the immune system, and LSEC may act as a
reservoir for endogenous re-infection. Furthermore, paracrine
signals released from LSEC can facilitate HCV replication.
One example is bone morphogenic protein 4 (BMP4), whose
expression is low in normal liver since it is negatively regulated
by VEGFR2 activation, but is upregulated in CLD due to
reduced VEGFR2/p38 MAPK signalling (Rowe et al., 2014). LSEC




Maintenance of the LSEC phenotype is crucial for them to
carry out their physiological function and maintain homeostasis
(Figure 1), yet a common response to chronic injury is the
development of capillarisation. Sinusoidal capillarisation is the
process by which LSEC lose their fenestrated morphology
and adopt a more “capillary-like” phenotype. Capillarisation is
associated with basement membrane synthesis, loss of GATA4-
dependent signals and upregulation of CD31 and VCAM1
(Xu et al., 2003; Shetty et al., 2018). Following production of
substantial basement membrane, the phenotypic alterations in
LSEC become virtually irreversible. Capillarisation is analogous
with endothelial dysfunction, in which LSEC can no longer
maintain HSC quiescence in response to shear stress signals
(Deleve et al., 2008; Xie et al., 2012), and together these processes
precede fibrosis (Horn et al., 1987; Fraser et al., 1991; Pasarín
et al., 2012; Baiocchini et al., 2019). A recent study, however,
showed that LSEC dysfunction and loss of fenestrations following
chronic metabolic stress do not always go hand in hand (Kus
et al., 2019). Specifically, it was shown that mice subject to high-
fat diet developed non-alcoholic fatty liver disease (NAFLD)-like
disease characterised by steatosis, weight gain, insulin resistance
and a pro-inflammatory LSEC phenotype, yet LSEC bioenergetics
and fenestrae were functionally preserved. This demonstrates
the discernible ability of LSEC to adapt to metabolic stress and
pro-inflammatory burden associated with NAFLD. Nevertheless,
there is compelling evidence to suggest that capillarisation
and endothelial dysfunction not only precede fibrosis, but also
promote it (Figure 5).
It is well-documented that fenestrations are altered in
pathophysiological conditions (Horn et al., 1987; Clark
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FIGURE 4 | LSEC actively contribute to the tumour microenvironment during HCC and liver metastasis. Left: LSEC promote an immunosuppressive
microenvironment and thus, HCC development and progression. (1) LSEC presentation of tumour antigens to CD8+ T cells via MHCI induces tolerogenic
responses, in the presence of PDL1, which is upregulated in HCC tumours. (2) Production of IL-10 by LSEC induces Treg, which are recruited via Stab1, undergoing
transmigration and inhibiting Teff responses. (3) Treg are also induced by MDSCs, which accumulate in HCC due to LSEC production of CXCL1 and CXCL2. MDSCs
elicit pro-tumourigenic effects including inhibition of T cell activation, NK cell inhibition, and stimulation of angiogenesis. (4) Transdifferentiated LSEC lose expression
of LSEC markers and upregulate expression of adhesion molecules VCAM-1, CD151, VAP-1 and ICAM-1, which facilitates leukocyte recruitment. (5) Transformed
malignant hepatocytes enhance CCL2, CCL3, and CXCL10 secretion, further promoting leukocyte recruitment. (6) Hypoxia-induced production of CCL20 by
hepatomas inhibits T cell proliferation. (7) LSEC production of adipokines, such as FABP4, in response to hypoxia and VEGF exert pro-oncogenic effects by inducing
hepatocyte proliferation. These effects can be attenuated with FABP4-specific inhibitor BMS309403. (8) LSEC also foster conditions which promote
pro-tumourigenic angiogenesis, including recruitment of pro-angiogenic BM EPC, AEP production and expression of T-cadherin in response to hepatoma- and
MDSC-derived FGF. (9) Anti-inflammatory TAM also promote immunosuppression and angiogenesis. Right: LSEC orchestrate formation of a pre-metastatic niche
which promotes development of secondary liver tumours. (1) Blood-borne cancer cells can become entrapped within LSEC fenestrae and accumulate in the
sinusoidal lumen. (2) Tumour cells promote LSEC secretion of pro-metastatic mediators such as MIF, IL-1 and CXCL12, as well as (3) activation of KC which
produce pro-inflammatory cytokines that in turn activate LSEC. TNFR inhibition has been shown to prevent liver metastasis in mice. (4) Activated LSEC upregulate
expression of adhesion molecules which promotes binding and invasion of cancer cells to the space of Disse, where they are generally protected from KC and NK
cells within the sinusoids. Wnt-independent Notch activation has been shown to inhibit tumour cell adhesion. (5) LSEC secrete FN which interact with α9β1 integrin
on cancer cells, initiating EMT and promoting metastatic spread. (6) LSEC also express L-SIGN and LSECtin, which are upregulated in liver metastasis and mediate
adhesion and migration of cancer cells. L-SIGN blockade reduces colon cancer metastasis in murine models. LSEC, liver sinusoidal endothelial cells; HCC,
hepatocellular carcinoma; MHCI, major histocompatibility complex I; PD-1, programmed cell death protein 1; PDL1, programmed death ligand 1; IL-10, interleukin
10; Treg, regulatory T cell; Stab1, stabilin-1; Teff, effector T cell; MDSC, myeloid-derived suppressor cell; CXCL1, C-X-C chemokine ligand type 1; NK, natural killer
cell; VCAM-1, vascular cell adhesion molecule 1; VAP-1, vascular adhesion protein 1; ICAM-1, intercellular adhesion molecule 1; CCL2, C-C chemokine ligand type
2; FABP4, fatty acid binding protein 4; VEGF, vascular endothelial growth factor; BM EPC, bone marrow erythroid progenitor cells; AEP, asparaginyl endopeptidase;
FGF, fibroblast growth factor; TAM, tumour-associated macrophage; HSC, hepatic stellate cell; TGFβ, transforming growth factor β; MIF, macrophage migration
inhibitory factor; KC, Kupffer cell; TNFα, tumour necrosis factor α; TNFR, tumour necrosis factor receptor; FN, fibronectin; EMT, epithelial-to-mesenchymal transition;
L-SIGN, lymph node-specific ICAM-3 grabbing non-integrin; LSECtin, lymph node sinusoidal endothelial cell C-type lectin.
et al., 1988; Fraser et al., 1991; Xu et al., 2003; Baiocchini
et al., 2019). Fenestrations also decrease with age (Ito et al.,
2007), a process dependent on p53 and p19ARF- dependent
signalling (Koudelkova et al., 2015) which is associated with
pseudocapillarisation, sinusoidal dysfunction, loss of vasodilatory
capacity, and increased hepatic vascular resistance (Dg et al.,
2007; Jamieson et al., 2007; Maeso-Diaz et al., 2018). As eluded to
above, fenestrations are dynamic structures which are regulated
by several factors and pathways. Studies have shown that
cross-talk between LSEC and other hepatic cells can result in
loss of fenestrations, for example, LSEC-KC interactions were
shown to elicit fenestration loss and upregulation of CD31 (Ford
et al., 2015). Additionally, a recent study implicated BMP9, a
paracrine factor produced by HSC, as a key regulator of LSEC
fenestrations (Desroches-Castan et al., 2019). It was shown that
BMP9 maintains vascular quiescence via interactions with its
receptor ALK1, and that BMP9 genetic deletion drives LSEC
capillarisation and development of perisinusoidal fibrosis in
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FIGURE 5 | Liver disease follows a common pathway of progression which results in fibrogenesis that is both preceded and driven by LSEC capillarisation and
dysfunction. This figure summarises the common disease pathways discussed in this review, highlighting various approaches for potential therapeutic intervention.
These include: (1) molecules which maintain LSEC homeostasis, such as BMP9, statins and phosphodiesterase inhibitors; (2) anti-angiogenics which are also
anti-inflammatory and anti-fibrotic, such as L1-10, AT-II inhibition and sorafenib; (3) anti-fibrotics, including anti-VAP1 and Hh inhibition; (4) and targets involved in
leukocyte recruitment. LSEC, liver sinusoidal endothelial cells; HCC, hepatocellular carcinoma; BMP9, bone morphogenic protein 9; VEGF, vascular endothelial
growth factor; NO, nitric oxide; sGC, soluble guanylate cyclase; PDE, phosphodiesterase; AT-II, angiotensin II; VAP-1, vascular adhesion protein 1; Hh, hedgehog;
HSC, hepatic stellate cell.
mice. Moreover, addition of exogenous BMP9 to LSEC primary
cultures prevented fenestration loss and preserved GATA4 and
PLVAP expression.
Behaviour of endothelial cells is regulated largely by
mechanical cues of shear stress which is influenced by blood flow
through the lumen of the sinusoids (Figure 1). Despite low flow
rate, shear stress is generated due to the narrow diameter of the
sinusoids. Increasing levels of shear stress result in NO synthesis
by LSEC which in turn act to limit vascular resistance by causing
vasodilation. Furthermore, the NO signalling pathway maintains
the LSEC differentiated phenotype in an autocrine fashion, which
is thought to be mediated by the VEGF signalling pathway
(DeLeve et al., 2004). Dysfunctional LSEC have impaired eNOS
activity, meaning vasodilation switches to vasoconstriction, thus
increasing intrahepatic vascular resistance (Rockey and Chung,
1998; Francque et al., 2012). As a compensatory mechanism,
LSEC in cirrhotic livers overexpress KLF2 to manage vascular
dysfunction, although eventually this is insufficient in preventing
portal hypertension and exacerbation of cirrhosis (Gracia-Sancho
et al., 2011; Marrone et al., 2013, 2015). Restoration of the NO-
dependent pathway via simvastatin (Marrone et al., 2013, 2015;
Wang et al., 2013) or sildenafil (Tateya et al., 2011) treatment was
shown to improve liver inflammation in rodent steatosis models.
Similarly, LSEC differentiation can be re-established by treatment
with soluble guanylate cyclase (sGC) activator, BAY-60-2770,
which leads to HSC quiescence and attenuation of cirrhosis in
rats (Xie et al., 2012).
These pertubations in mechano-sensing by LSEC drive fibrotic
processes (Ford et al., 2015; Soydemir et al., 2019) and changes
in hepatic blood pressure and liver stiffness occur soon after
hepatic injury (Georges et al., 2007). Biophysical characteristics of
the ECM and matrix stiffness are key mechanisms in mediating
HSC activation contributing to fibrogenesis (Sakata et al., 2004;
Olsen et al., 2011). In addition to effects on HSC, mechanical
stiffness also impacts hepatocyte phenotype, which is important
for regulating cellular responses to tissue injury (Natarajan et al.,
2017). Furthermore, mechanical cues are also thought to have
indirect effects on LSEC, including cytoskeletal remodelling, loss
of fenestrations and formation of stress fibers (Juin et al., 2013;
Ford et al., 2015). Hilscher et al. (2019) suggested that activation
of PIEZO channels, triggered by integrins and myosin filaments,
may be an underlying factor allowing LSEC to respond to
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changes in shear stress and pressure. Briefly, authors showed that
expression of Notch-dependent transcription factors HES1 and
HEY1 resulted in neutrophil recruitment via CXCL1 secretion,
a mechanism thought to drive microthrombus formation and
portal hypertension in mice. Additionally, activated HSC further
increase tissue stiffness by depositing more ECM, further driving
mechano-activation (Soydemir et al., 2019). Drugs that intervene
with this mechano-sensitive positive feedback cycle could show
therapeutic promise for the treatment of fibrosis.
Notch signalling has previously been shown to exacerbate
LSEC capillarisation via downregulation of the eNOS/sGC
pathway (Duan et al., 2018). Notch ligand DLL4 (delta-like
ligand 4), which is upregulated in LSEC from cirrhotic patients
and carbon tetrachloride (CCl4)-treated mice, and has been
shown to drive loss of fenestrations and deposition of basement
membrane (Chen et al., 2019). The overexpression of DLL4
during liver fibrosis was linked to upregulation of ET-1 and
enhanced HSC sinusoidal coverage, which was thought to be
initiated by hypoxic conditions associated with fibrogenesis.
This validates the Notch pathway and its ligands as potential
fibrotic targets, since DLL4 knockdown ameliorated LSEC de-
differentiation and provided protection against CCl4-induced
fibrosis. Contrastingly, Dill et al. (2012) have demonstrated
vascular remodelling as a result of disrupted Notch1 signalling,
and that maintenance of this signalling pathway conserves the
LSEC highly differentiated phenotype. More research is required
to fully elucidate the role of Notch signalling in maintenance or
alteration of the LSEC phenotype.
An additional pathway that drives LSEC dysfunction is the
hedgehog signalling pathway (Xie et al., 2013). Production of
hedgehog molecules and other mediators (e.g., transforming
growth factor β (TGFβ), laminin and fibronectin) by LSEC
activate HSC, which in turn produce hedgehog-containing
microparticles that interact with LSEC to further enhance
hedgehog signalling (Witek et al., 2009; Xie et al., 2013). Thus,
inhibition of hedgehog signalling prevents LSEC capillarisation
and restores the differentiated LSEC phenotype (Xie et al., 2013;
Zhao et al., 2017). Collectively, these findings exemplify the
intimate cross-talk between LSEC and HSC, and the vicious
cycle of endothelial dysfunction and HSC activation, which
perpetuates fibrogenesis (Figure 5).
Angiogenesis
The formation of new blood vessels, known as angiogenesis, is a
key feature of CLD and HCC that is often associated with areas
of fibrogenesis (Coulon et al., 2011; Paternostro et al., 2010).
Whilst angiogenesis is a physiological process that is crucial for
maintaining homeostasis, in the context of inflammation and
endothelial dysfunction, angiogenesis becomes pathological in
that it exacerbates fibrotic processes. It is thought that LSEC
capillarisation and dysfunction precedes fibrogenesis, that in turn
drives angiogenesis, which ultimately perpetuates inflammation
and fibrosis (Figure 5) (Kitade et al., 2008, 2009). This is
exemplified by the anti-fibrotic action of anti-angiogenic drugs.
Chronic inflammation promotes angiogenesis by several
mechanisms, including sustaining hypoxia and inducing
transcription of angiogenic hypoxia-inducible factor 1α
(HIF1α)-dependent genes and VEGF (Hammoutene and
Rautou, 2019). LSEC actively participate in pathological hepatic
angiogenesis by releasing pro-angiogenic factors VEGF (Yoshiji
et al., 2003), angiopoietins (Taura et al., 2008; Lefere et al., 2019)
and adipokines (Kitade et al., 2006) in response to hypoxia, liver
injury, inflammation and fibrosis (Zhang et al., 2015). It is known
that NRP-1 initiates pro-fibrogenic signalling by promoting
HSC activation. A recent study has also implicated NRP-1 in
angiogenesis during liver cirrhosis, by upregulation of VEGFR2
expression and activation via PI3K/Akt signalling in LSEC (Wang
et al., 2019). Interestingly, NRP-1 and VEGFR2 complex with
PLVAP during foetal angiogenesis (Auvinen et al., 2019); whether
PLVAP may also drive angiogenesis in adult liver remains to be
determined. CD147 has also been shown to promote fibrosis by
enhancing hepatic angiogenesis via VEGF-VEGFR2 signalling,
which mediated hepatocyte-LSEC cross-talk (Yan et al., 2015).
However, when targeting VEGF signalling it should be borne in
mind the cell- and context-dependent effects of this approach,
since inhibition of VEGFR2 in myeloid cells could both prevent
angiogenesis and fibrosis whilst simultaneously hindering LSEC
degradation of the ECM and fibrosis resolution (Yang et al., 2014;
Kantari-Mimoun et al., 2015).
Angiopoietin-2/Tie2 interactions have been implicated
in pathological angiogenesis in non-alcoholic steatohepatitis
(NASH), since peptibody L1-10 reduced hepatic angiogenesis
and restored normal vascular microarchitecture. In addition,
L1-10 treatment downregulated endothelial adhesion molecules
VCAM-1, ICAM-1 and monocyte chemoattractant protein
1 (MCP-1), which was also observed in other CLD models
including CCl4 treatment and bile duct ligation (Lefere et al.,
2019). In the same respect, angiotensin II (AT-II) receptor
inhibition with candesartan inhibits liver angiogenesis and
fibrosis (Yoshiji et al., 2006; Tamaki et al., 2013), whilst anti-
VEGFR2 antibodies normalise liver vasculature and reduce
inflammatory gene expression in the liver (Coulon et al., 2013).
The natural anti-fibrotic compound, Fuzheng Huayu, has been
shown to mitigate CCl4-induced sinusoidal capillarisation,
angiogenesis and expression of angiogenic factors CD31, VEGF,
VEGFR2, pERK, and HIF-1α, ultimately reducing liver injury
and fibrosis in CCl4-treated mice (Liu et al., 2019). Furthermore,
targeting of VEGF expression by HSC using compounds such
as curcumin (Zhang et al., 2014) and nintedanib (Ozturk
Akcora et al., 2017) has also shown to attenuate fibrosis.
Inhibition of hedgehog signalling with tetramethylpyrazine
reduced angiogenesis and alleviated fibrosis in vitro and in vivo
(Zhao et al., 2017). This was thought to be mediated, at least
in part, by restoration of LSEC fenestration and decreased
expression of angiogenic markers VEGFA and VEGFR2 as well
as endothelial markers CD31 and CD34. These data further
support the targeting of angiogenesis to elicit anti-inflammatory
and anti-fibrotic effects.
Angiocrine Factors
Angiocrine factors produced by endothelial cells mediate organ
homeostasis, self-renewal and stem cell differentiation, as well as
orchestrating tumour growth and metastasis (Figure 4) (DeLeve,
2013). LSEC production of angiocrine signals is tightly regulated
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and determines the balance between regeneration and fibrosis in
response to acute and chronic liver injury. These are mediated by
the CXCR7-Id1 and CXCR4 pathways, respectively (Ding et al.,
2014). Indeed, poor hepatocyte regeneration correlates with both
cellular and functional loss of liver endothelial cells and a decrease
in CXCR7-Id1 and HGF expression during acute-on-chronic
liver failure (Shubham et al., 2019).
LSEC release HGF and Wnt2 which regulate the functional
maintenance and regeneration of hepatocytes. These angiocrine
factors are regulated by the VEGF-Id1 axis, since HGF and
Wnt2 are not upregulated following partial hepatectomy in
Id1 knockout mice (Ding et al., 2010). Further, treatment of
LSEC with mitogenic neuropeptide substance P was shown to
not only improve endothelial cell viability, proliferation and
production of NO/HGF, but also ameliorated TNFα-induced
endothelial dysfunction and promoted hepatocyte regeneration
(Piao et al., 2019). Interestingly, there is some evidence to suggest
that it is not mature LSEC which drive regeneration in the liver,
but rather bone marrow-derived progenitor cells of the sinusoidal
endothelium. VEGF-SDF1α signalling following liver injury or
partial hepatectomy results in recruitment of CXCR7+ bone
marrow-derived sinusoidal endothelial progenitor cells which
mediate liver regeneration (DeLeve et al., 2016).
Endothelial-to-Mesenchymal Transition
Alongside LSEC phenotypic changes and angiogenesis,
there is also evidence to suggest that fibrosis may be
driven by endothelial-to-mesenchymal transition (EndMT).
The mechanisms by which endothelial cells convert into
myofibroblasts is referred to as EndMT, which contributes to
ECM deposition and fibrogenesis in liver disease. Healthy LSEC
produce modest amounts of collagen type IV and fibronectin
under steady state conditions. During liver fibrosis, ECM
production increased several-fold but the composition remains
relatively consistent (Natarajan et al., 2017). Exposure of LSEC to
interstitial collagen fibers and laminin results in defenestration
(McGuire et al., 1992; Shakado et al., 1995). Interestingly, culture
of LSEC on decellularised liver ECM maintained their fenestrated
phenotype for longer periods compared to ECM from other
organs (Sellaro et al., 2007).
The production of TGFβ, collagens, fibronectin and laminin
by capillarised LSEC may be considered EndMT (Maher and
McGuire, 1990; Neubauer et al., 1999), a process characterised by
co-expression of CD31 and α-sma (Ribera et al., 2017). EndMT
occurs when endothelial cells undergo a series of molecular
events and gain a mesenchymal (e.g., myofibroblastic) phenotype,
and is a characteristic of many fibrotic diseases (Piera-Velazquez
et al., 2016), including cardiovascular and pulmonary disease.
However, only a handful of studies have demonstrated EndMT
in vivo in cirrhotic patients (Dufton et al., 2017; Ribera et al.,
2017). These have been validated in CCl4 mouse models, where
it has been shown that EndMT is mediated by TGFβ – SMAD3
signalling and can be attenuated by BMP7 and etanercept (TNFα
inhibitor) treatment (Dufton et al., 2017; Ribera et al., 2017).
Decreased EndMT in response to BMP7 treatment correlated
with attenuated fibrosis and improved vascular disorganisation
(Ribera et al., 2017).
Li Z. et al. (2019) recently showed that inhibition, or
endothelial-specific deletion, of transcriptional modulator MKL1
suppresses TGFβ-induced EndMT and associated fibrosis.
The driving effect of MKL1 on EndMT was shown to be
mediated by recruitment to the promoter region of TWIST1,
activating its transcription in a STAT3-dependent manner. Both
STAT3 and TWIST1 inhibition, with C188-9 and harmine,
respectively, reversed EndMT and bile duct ligation-induced
fibrosis in mice, proposing the STAT3-MKL1-TWIST1 axis
as a novel fibrogenic pathway with potential for therapeutic
targeting. In contrast, endothelial transcription factor (ETS)-
related gene (ERG) protects against EndMT by preferentially
driving SMAD1 signalling and repressing SMAD3 activity, whilst
ERG genetic ablation drove EndMT and spontaneous liver
fibrosis (Dufton et al., 2017). Furthermore, decreased ERG
expression correlated with EndMT in end-stage liver disease
patients (Dufton et al., 2017), suggesting it could be a valid
biomarker for assessing EndMT in liver disease.
Clinical studies and animal models suggest that fibrosis
can be reversible (Soyer et al., 1976; Hammel et al., 2001;
Arthur, 2002; Dixon et al., 2004; Issa et al., 2004). One
therapeutic approach is aimed at degradation of the ECM
through targeting of matrix metalloproteinases (MMPs) and
tissue inhibitors of metalloproteinases (TIMPs) (Clutterbuck
et al., 2009; Roderfeld, 2018). Chronic hepatitis patients have
lower circulating levels of collagenase, MMP-1, and excess TIMP-
1 which positively correlates with aminotransferase levels and
fibrosis score (Ninomiya et al., 2001; Flisiak et al., 2004; Guido
et al., 2006). Increasing the MMP-1/TIMP-1 ratio has shown
promise in chronic hepatitis B and C patients (Ninomiya et al.,
2001; Flisiak et al., 2004; Guido et al., 2006). Further, studies
in rats have shown that transient overexpression of MMP-1
decreases type I collagen, induces hepatocyte proliferation, and
attenuates fibrosis (Iimuro et al., 2003), whilst anti-TIMP-1
antibody treatment reduced collagen accumulation and α-sma
expression (Parsons et al., 2004). This is interesting as LSEC,
along with HSC, possess MRs which can endocytose denatured
collagen α chains from the circulation and space of Disse
(Malovic et al., 2007; Madsen et al., 2012). However, MMPs are
also implicated in fibrogenesis; their pleiotropic roles in fibrosis
have been systematically reviewed (Hemmann et al., 2007). For
instance, in mice, MMP-9 has been implicated in activation of
latent TGFβ, a process which can drive HSC activation and
subsequent collagen deposition, thereby promoting fibrosis (Yu
and Stamenkovic, 2000). Nevertheless, it seems that LSEC which
have undergone EndMT contribute to fibrogenesis, whilst LSEC
which maintain their differentiated phenotype contribute to
fibrinolysis and resolution.
Autophagy
The process of EndMT and TGFβ signalling have been linked
to autophagy which is the process of regulated degradation and
recycling of intracellular components. Upregulation of TGFβ
signalling and EndMT can be induced by loss of autophagy
genes, ATG7 and ATG4B, which has been shown to exacerbate
inflammation and fibrosis in murine models of cardiac (Li et al.,
2016), pulmonary (Cabrera et al., 2015; Singh et al., 2015), renal
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(Nam et al., 2019a,b), and pancreatic (Zhou et al., 2017) fibrosis.
Conflictingly, autophagy has also been defined as a driver of
fibrotic disease (Hernandez-Gea et al., 2012; Ghavami et al., 2015;
Livingston et al., 2016). Ruart et al. (2019) investigated the role
of autophagy in regulating endothelial dysfunction during liver
injury. The authors showed that LSEC homeostasis is maintained
by autophagy, a process which protects against oxidative stress,
that is rapidly upregulated following capillarisation in vitro
and in vivo. Selective loss of endothelial autophagy resulted in
reduced intrahepatic NO and subsequent cellular dysfunction
which perpetuated fibrosis in CCl4-treated mice.
In keeping with these findings, defective autophagy pathways
in LSEC have been shown to occur in NASH patients
compared with controls and steatotic patients. Autophagy
deficiency was linked to liver inflammation, EndMT, apoptosis
and perisinusoidal fibrosis in a mouse model of NAFLD,
outcomes that were independent of metabolic risk factors
such as body weight and plasma cholesterol (Hammoutene
et al., 2020). Furthermore, activation of autophagy with
hypercholesterolaemia drug ezetimibe, via AMPK activation and
nuclear translocation of transcription factor TFEB, ameliorated
steatohepatitis by dampening inflammasome signalling in
macrophages (Kim et al., 2017). In contrast, autophagy in HSC
has been shown to release lipids that promote fibrogenesis
(Hernandez-Gea et al., 2012). Thus, the role of autophagy in
hepatic fibrosis seems to be cell-specific, with LSEC (Ruart et al.,
2019), macrophage (Kim et al., 2017), and hepatocyte (Singh
et al., 2009) autophagy providing a protective role, and autophagy
in HSC proving detrimental (Hernandez-Gea et al., 2012). This
should be considered when designing compounds which target
autophagy for fibrotic indications.
LSEC IN THE TUMOUR
MICROENVIRONMENT
Both the structure and function of LSEC render them capable
of playing an active role in contributing to the tumour
microenvironment (TME) and in the development of primary
liver cancer (Figure 4). Of note, the liver is a strongly
immunosuppressive environment which acts as protection
against inflammation derived from gut antigens. However, the
same mechanisms that prevent liver inflammation can foster
conditions which promote tumour development.
As discussed previously, LSEC are able to cross-present soluble
antigen on their MHCI to CD8+ T cells. Due to co-inhibitory
signalling, CD8+ T cells initially activated by LSEC regain a
quiescent state in which they are unable to exert cytotoxic effects
upon circulating tumour cells or antigens (Diehl et al., 2008).
Thus, LSEC induce tolerance of CD8+ T cells toward antigens
(Limmer et al., 2000). Moreover, Berg et al. (2006) demonstrated
that LSEC are able to induce tolerance toward tumour cells, and
Höchst et al. (2012) found that LSEC are involved in tolerance
toward carcinoembryonic antigen (CEA), which is associated
with colorectal carcinoma. Another mechanism by which the
liver sinusoids might be pro-tumourigenic is via the TGFβ-
dependent induction of Treg (Carambia et al., 2014).
LSEC transdifferentiation and the loss of several LSEC
markers are hallmarks of HCC (Figure 4). Lymphocyte
recruitment is promoted by the expression of ICAM-1, VAP-
1 and CD151 (Wadkin et al., 2017), and Treg are specifically
recruited by stabilin-1 (Shetty et al., 2011). Hepatocyte malignant
transformation enhances the secretion of chemokines (Yoong
et al., 1999) (including CXCL10, CCL2, and CCL3) and adhesion
molecule expression (Yoong et al., 1998) (ICAM-1 and VAP-
1) by LSEC, which in turn promotes leukocyte recruitment. As
such, HCC tumour tissue is characterised by CD8+, CD68+, and
FoxP3+ immune cell infiltrate, particularly within the invasive
margin. The expression of PD-L1 on LSEC correlated with both
the incidence of CD8+ T cells and poor survival outcomes
(Ihling et al., 2019). This suggests that HCC may evade immune
responses via the upregulation of PD-L1 in response to pre-
existing cytotoxic T-lymphocyte activity.
The distinction in the TME between primary liver cancer,
which usually arises on a background of chronic liver
inflammation, and liver metastases, which arise from an
otherwise healthy liver, has been recently reviewed (Figure 4)
(Eggert and Greten, 2017). In HCC, both the tumour itself and
the underlying chronic inflammation contribute to the TME.
Hypoxia, for example, an early event in the development of liver
cirrhosis, promotes an immunosuppressive microenvironment.
This is relevant in tumourigenesis, where hypoxia induces
tumour cells to secrete CCL20, which subsequently inhibits T cell
proliferation (Ye et al., 2016). A recent study also highlighted
the key role that LSEC play in balancing hepatic immune cell
populations through chemokine presentation (Ma et al., 2018).
In this study the investigator showed that LSEC presentation
of the chemokine CXCL16 was critical in regulating the anti-
tumour response of NKT cells in models of primary and
metastatic liver cancer.
One of the earliest mechanisms by which the liver is
primed for metastasis is by the accumulation of myeloid cells
and myeloid-derived suppressor cells (MDSCs) in the liver
(Connolly et al., 2010). MDSCs are immature cells of myeloid
origin which have been shown to accumulate in the TME
of HCC (Hoechst et al., 2008) and contribute significantly to
promoting an immunosuppressive niche (Gabrilovich, 2017).
MDSCs exhibit pro-tumoural and pro-metastatic effects via a
number of diverse mechanisms, including suppression of T
cell activation, inhibition of NK cell activity and induction
of Treg (Gabrilovich, 2017; Millrud et al., 2017). MDSCs also
promote tumourigenesis by remodelling of the TME and tumour
angiogenesis via production of VEGF, basic fibroblast growth
factor, Bv8, and MMP9 (Ley et al., 2007; Millrud et al., 2017).
Chemokines including CXCL1 and CXCL2 are secreted by LSEC,
which are involved in the recruitment of MDSCs to the tumour
microenvironment (Brodt, 2016). In HCC, MDSC incidence
within tumours directly correlated with disease progression and
mortality (Lu et al., 2019).
Metabolism in HCC
In the last few years there has been major interest in the
role of metabolism in regulating immunity. It is now accepted
that metabolic pathways shape immune responses rather than
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having a mere bystander role. In turn, metabolic factors,
such as altered adipokine signalling and lipid metabolism
observed in NASH-associated cirrhotic patients, are linked
to inflammation-induced cancer. For instance, linoleic acid
accumulation mediates selective loss of intrahepatic CD4+ T
cells by inducing oxidative stress, which in turn accelerates HCC
growth due to impaired anti-tumour surveillance (Ma et al.,
2016). The metabolic role of LSEC in lipid metabolism is also
likely to contribute to the development of HCC. For example,
fatty acid binding protein 4 (FABP4), produced by LSEC in
response to hyperglycaemia, VEGF and hypoxia, is increased
in NAFLD and HCC patients (Milner et al., 2009; Laouirem
et al., 2019). This adipokine exerts pro-oncogenic effects by
inducing hepatocyte proliferation, thus enabling HCC to develop
in the NAFLD setting (Laouirem et al., 2019). Whilst metformin
treatment reduced FABP4 upregulation in vitro, specific FABP4
inhibitor BMS309403 reduced tumour growth in vivo in murine
xenograft models (Laouirem et al., 2019). Adipokines are also
known to induce angiogenesis which promotes HCC growth,
further highlighting them as a potential target for HCC treatment
on a background of NASH. More work is still required to
understand how the well-established metabolic role of LSEC
impacts the immune and angiogenic environment that supports
tumour development within the liver.
Angiogenesis in HCC
Angiogenesis is a hallmark of all neoplasia, as it facilitates
tumourigenesis and metastasis; liver tumours are known to be
especially vascularised. During early HCC, there is a switch
in tumour blood supply from the portal vein which supplies
dysplastic and regenerative nodules as well as 70% of the blood
supply to a healthy liver, to the hepatic artery (Semela and
Dufour, 2004). There is a growing body of evidence to suggest
that LSEC have a role in angiogenesis in the development these
hypervascular tumours. HCC tumour progression is associated
with phenotypic changes in peri-tumoural LSEC and increased
production of angiogenic factors.
There is a strong correlation between changes in LSEC gene
expression and angiogenesis in HCC. Endothelial alterations
within and proximal to the tumour are associated with
HCC. There is a correlation between HCC and a loss of
LSEC markers including stabilin-1, stabilin-2, LYVE-1 and
CD32b, whilst increasing expression of integrins and ICAM-
1 and capacity for angiogenesis, coagulation and fibrinolysis
(Wu et al., 2008). Stabilin-2 is an LSEC marker protein;
loss of stabilin-2 expression in the endothelial cells of peri-
tumoural tissue conferred a significant overall survival advantage
(Géraud et al., 2013). It was suggested that this might
be via prevention of vascular remodelling and endothelial
cell transdifferentiation. Additionally, asparaginyl endopeptidase
(AEP), a molecule known to regulate tumour angiogenesis, is
absent or low in normal tissues. However, it has found to
be significantly upregulated in solid tumours and surrounding
ECM, promoting LSEC angiogenesis in vitro (Li N. et al.,
2019). Therefore, AEP may represent a novel target for
progression of CLD and HCC.
The highly angiogenic nature of HCC is associated with
increased classical growth factors such as VEGF and PDGF,
whilst classical adhesion molecules such as ICAM-1 and
VCAM-1 are preferentially expressed on tumour tissue. It has
been shown that bone marrow-derived erythroid progenitor
cells (BM-EPCs) play a prominent role in HCC angiogenesis
(Zhu et al., 2012). LSEC expression of distinct adhesion
molecules and growth factors could drive BM-EPCs recruitment,
especially since BM-EPC homing to tumour tissue is thought
to be via cellular adhesion molecules ICAM-1, VCAM-1,
and VEGF.
Another growth factor, FGF2, secreted by HCC and expressed
preferentially in tumour tissue compared to CLD, induces
T-cadherin on LSEC. T-cadherin is selectively over-expressed
in intra-tumoural capillary endothelial cells in many HCC
specimens (Adachi et al., 2006). In vitro, T-cadherin was
found to influence the invasive potential of HCC (Riou
et al., 2006), via binding of adiponectin and activation of
NFκB, thus preventing tumour cell apoptosis. This suggests
T-cadherin might be a mediator of angiogenesis in HCC.
Another suggested mediator of angiogenesis is the leukocyte
cell-derived chemotaxin 2 (LECT2)-Tie1 signalling pathway,
which possesses pleiotropic effects in HCC. On one hand,
loss of LECT2 promotes inflammatory monocyte recruitment,
suggesting its activity supports an immunosuppressive TME,
whilst on the other it acts as a tumour suppressor by
inhibiting vascular invasion (Chen et al., 2014). In the context
of CLD, LECT2-Tie1 signalling is an important driver of
fibrosis by promoting LSEC capillarisation and inhibiting portal
angiogenesis (Xu et al., 2019). Consistent with these findings,
serum levels of LECT2 are significantly elevated in cirrhotic
and HCC patients (Slowik et al., 2019) and correlate with
fibrosis stage (Xu et al., 2019), highlighting its usefulness as a
potential biomarker or therapeutic target for these indications
(Su and Iwakiri, 2020).
Targeting angiogenesis has shown promise in the management
of cancer, and current medical therapies focus on this aspect
in the setting of HCC. For many years, sorafenib represented
the only medical treatment for HCC and increased median
survival in advanced HCC by 3 months (SHARP trial) (Llovet
et al., 2008). Sorafenib is a multi-kinase inhibitor which acts
on VEGF, PDGF and Raf. After a decade as the only approved
oral agent for HCC, a second multi-kinase inhibitor, lenvatinib,
has now shown to be non-inferior to sorafenib (Kudo et al.,
2018). There have been many pre-clinical studies to assess
how combinations of anti-angiogenics and other agents may
boost therapeutic efficacy. For example, sorafenib inhibits the
formation of pre-neoplastic lesions in rat NAFLD models,
and combination with AT-II receptor antagonist losartan also
had this effect (Yoshiji et al., 2014). AT-II inhibition reduces
HIF-1α activity and expression of VEGF which prevents
angiogenesis and HCC development in rats (Yoshiji et al., 2006;
Tamaki et al., 2013). Inhibition of angiopoietin-2 with L1-
10 peptibody reduced angiogenesis, ameliorated steatohepatitis
and prevented NASH-associated HCC progression in mice
(Lefere et al., 2019). Furthermore, leptin-mediated angiogenesis
is known to regulate HCC development and progression
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(Kitade et al., 2006), and so targeting this adipokine may
represent a potential additional anti-angiogenic approach. A key
breakthrough in the rationale of targeting vasculature, such as
LSEC, in tumour development has come from studies combining
immunotherapy and anti-angiogenics, with major interest in the
combination of checkpoint inhibitors and anti-VEGF therapies
(Hato et al., 2016).
LSEC IN LIVER METASTASIS
The liver is also the main site of metastasis from a number of
primary tumours, including colon, pancreatic and lung (Budczies
et al., 2015; Mielgo and Schmid, 2020). The presence of liver
metastases is a poor prognostic marker and therefore, there is
an urgent need to understand how liver metastases develop, and
subsequently identify potential therapeutic targets.
There are four main stages in the development of liver
metastases: (i) the microvascular phase, (ii) the extravascular
phase, (iii) the angiogenic phase, and (iv) the growth phase. It has
been established that tumours “prime” the sites of metastasis. The
role of the TME is well-established in liver metastasis, as is the
concept of the pre-metastatic niche, in which the TME creates a
prime setting for metastases to seed (Figure 4) (Van den Eynden
et al., 2013; Brodt, 2016; Mielgo and Schmid, 2020).
LSEC, KC, and NK cells are the first barrier encountered by
circulating metastatic cells, forming a natural defense against
seeding blood-borne cancer cells. The physical entrapment of
tumour cells in the fenestrae of LSEC leads to mechanical stress
and deformation. Larger clumps of tumour cells can become
trapped in sinusoidal vessels, resulting in localised ischemia-
reperfusion, thus triggering the release of NO (Wang et al.,
2000) and reactive oxygen species (ROS) from both LSEC
and KC (Yanagida et al., 2006). This subsequently results in
widespread apoptosis; it has been suggested that up to 95%
of circulating tumour cells which encounter LSEC undergo
apoptosis (Vekemans et al., 2004).
However, LSEC represent a double-edged sword in liver
metastasis. They possess a number of pro-metastatic qualities.
Tumour cells promote KC secretion of pro-inflammatory
cytokines including TNFα and IL-1. These cytokines stimulate
LSEC to upregulate the expression of cellular adhesion molecules
including ICAM-1, VCAM-1, endothelial (E)-selectin, and CD31
(Clark et al., 2016). These cellular adhesion molecules can
facilitate cancer cell migration to the space of Disse, where
there is relative protection from NK and KC (Glinskii et al.,
2005). Specifically, cellular adhesion molecules enable tumour
cell attachment to LSEC, which in turn promotes tumour
cell arrest, extravasation and ultimately, the development of
metastasis (Auguste et al., 2007). The proposed mechanisms by
which these events occur are detailed below.
The Role of ICAM-1
Metastatic growth is dependent on tumour-host cell interactions
and LSEC are known as key players in this cross-talk. One
adhesion molecule shown to be involved in this cross-talk is
ICAM-1, which is the main cellular adhesion molecule expressed
on LSEC, KC, HSC, and hepatocytes (Zhu and Gong, 2013).
ICAM-1 is upregulated by pro-inflammatory cytokines including
TNFα, IL-1β, and IFN-γ.
ICAM-1 is a key player in the metastatic process in a number
of organs, including lung, liver and blood (Christiansen et al.,
1996; Kotteas et al., 2013). It is involved in the first stage
of metastasis: adhesion of tumour cells to the endothelial cell
wall (in the case of the liver, adhesion of tumour cells to
the surface of LSEC). Its expression promotes the activation
of pro-metastatic signalling pathways involving IL-6 and IL-8.
These pro-inflammatory cytokines increase vascular permeability
and further facilitate tumour cell adhesion to the endothelium,
thus forming a positive feedback loop promoting tumour
seeding and growth. ICAM-1 is also involved in tumour
cell extravasation via remodelling of the actin cytoskeleton
(Benedicto et al., 2017). In vivo, ICAM-1 is implicated in
the formation of liver metastases from colorectal cancer
(Benedicto et al., 2019), and mediates the infiltration of tumour
cells into tumour mass.
The Role of E-Selectin
The role of sinusoidal E-selectin has been examined by a number
of studies. E-selectin mediates the interaction of tumour cells
with endothelial cells and is thought to be a critical molecule in
tumour adhesion leading to the formation of metastases (Aychek
et al., 2008; Tremblay et al., 2008). This correlates clinically; there
is increased E-selectin expression found around liver metastases
from colorectal primary tumours (Ye et al., 1995). Alexiou et al.
(2001) found that elevated levels of E-selectin, ICAM-1 and
VCAM-1 correlated with disease outcome in colorectal cancer.
The Role of Other LSEC-Derived
Molecules
It has been shown that LSEC-derived cytokines, including IL-
1, macrophage migration inhibitory factor (MIF) and CXCL12
are pro-metastatic (Arteta et al., 2010; Mendt and Cardier,
2017). LSEC secrete fibronectin, which interacts with integrin
α9β1 on the surface of colorectal cancer cells, and induces
epithelial-to-mesenchymal transition (EMT) via upregulation
of Rac signalling pathways and activation of focal adhesion
kinase. This mechanism promotes the metastatic capability of
colorectal tumour cells (Ou et al., 2014). Kitakata et al. (2002)
found that TNFR1 (TNFα receptor)-deficient mice were 50% less
likely to develop liver metastases compared to wild-type mice.
Wild-type mice injected with tumour cells were found to have
significantly increased expression of VCAM-1 and E-selectin on
LSEC. Therefore, it is postulated that TNFα plays a key role in the
development of liver metastases via its upregulation of VCAM-1
and E-selectin on LSEC.
LSECtin, a C-type lectin, is an adhesion molecule mediating
interaction between LSEC and activated T cells. LSECtin is
upregulated in liver metastases from colorectal cancer. LSECtin
expression correlates with colonic tumour progression and the
development of hepatic metastases, which is proposed to be
via c-Met upregulation (Zuo et al., 2013). Additionally, lymph
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node-specific ICAM-3 grabbing non-integrin (L-SIGN/DC-
SIGNR/CLEC4M) and LSECtin have been implicated in adhesion
and migration of colon cancer cell metastasis to the liver (Liu
et al., 2004; Zuo et al., 2013; Na et al., 2017).
TARGETING LSEC IN INFLAMMATION
AND CANCER THERAPY
As detailed in the above paragraphs, LSEC are central to co-
ordination of the inflammation-cancer axis in the liver (Figure 5).
Since alteration in the LSEC phenotype is one of the earliest
events in fibrogenesis, and LSEC are known to both perpetuate
inflammation and foster the development of primary and
secondary liver tumours, they make an attractive target for CLD
and oncotherapy. Indeed, there have been recent advancements
in this field, notably in approaches aimed at targeting (i) LSEC
dysfunction and capillarisation, (ii) angiogenesis and angiocrine
signalling, and (iii) leukocyte and/or tumour cell adhesion
and transmigration.
Aforementioned approaches which could maintain LSEC
differentiation and function include restoration of their
fenestrated phenotype, via BMP9 and GATA4 (Geraud et al.,
2017; Desroches-Castan et al., 2019), re-constitution of the
VEGF/NO/sGC signalling pathway (Tateya et al., 2011; Xie
et al., 2012; Marrone et al., 2013, 2015; Wang et al., 2013),
and re-establishment of normal hedgehog signalling with
hedgehog inhibitors such as tetramethylpyrazine (Zhao et al.,
2017). Furthermore, maintenance of autophagy pathways,
which are known to be important for endothelial homeostasis
and are defective in CLD patients (Hammoutene et al., 2020),
may offer an additional treatment strategy. Conservation of
the LSEC phenotype and prevention of capillarisation may
reduce the risk of progression from inflammation and fibrosis
to irreversible cirrhosis and HCC. However, this approach
would require timely detection of disease to allow early
intervention and prophylaxis. This may be clinically challenging,
since liver disease is often initially silent, presenting only
in patients with advanced fibrosis. Nevertheless, inhibition
of LSEC capillarisation and dysfunction may impede the
feed-forward impact on HSC activation, thus promoting
fibrosis regression.
Angiogenesis in the context of fibrosis and tumourigenesis
has been discussed in this review. The anti-inflammatory
and anti-fibrotic effects of anti-angiogenic drugs is well-
documented, with some candidates showing promise for CLD
and cancer indications. These include peptibody, L1-10, which
interferes with angiopoietin-2/Tie2 interactions, AT-II inhibition
and multi-kinase inhibitors, sorafenib and lenvatinib, all of
which have shown to inhibit both angiogenesis and tumour
progression. Other potential targets include AEP and LECT2-
Tie1 signalling, although further work is required to validate
these candidates.
The recruitment of distinct leukocyte subsets by LSEC
presents an opportunity for potential liver- and cell-specific
therapeutic targets. Conventional adhesion molecules VCAM-1
and ICAM-1 are known to be upregulated in CLD and cancer,
which facilitate leukocyte recruitment. Anti-inflammatory drug,
resveratrol, inhibits VCAM-1 expression on tumour-activated
LSEC and reduced hepatic melanoma metastases by 75% in a
murine model (Salado et al., 2011). Furthermore, ICAM-1 has
been demonstrated to play a role in all stages of the metastatic
process from adhesion to immune evasion and colonisation.
Therefore, ICAM-1 blocking antibodies might represent an
avenue of therapeutic interest. To our knowledge, no group
has successfully translated ICAM-1 blockade in clinical studies,
owing to the challenges associated with inhibition of a cellular
adhesion molecule with such important roles in homeostasis
(Benedicto et al., 2017).
An alternative approach could be to target atypical adhesion
molecules, which are also increased during inflammation and
cancer, but display more organ-specific expression. These
atypical adhesion molecules include scavenger receptors and
VAP-1 which are detailed below. Pre-clinical studies suggest that
these endothelial receptors may have roles in recruiting specific
subsets of immune cells compared to the more global role of
ICAM-1 and VCAM-1. For example, stabilin-1 has been shown
to promote Treg recruitment (Shetty et al., 2011) and SCARF1
mediates adhesion of CD4+ T cells rather than CD8+ T cells
(Patten et al., 2017a), under conditions of physiological shear
stress, although their specific ligands on T cells are yet to be
identified. Endothelial stabilin-1 expression localises to sites
of leukocyte recruitment in inflamed liver and is also known
to orchestrate B cell recruitment, facilitating adhesion and
subsequent intravascular accumulation of B lymphoma cells
(Shetty et al., 2012). Targeting of stabilin-1 may therefore allow
modulation of the hepatic Treg pool or prevention of tumour
metastasis; indeed, genetic deficiency or antibody blockade
of stabilin-1 reduces immunosuppressive leukocytes within
tumours and halts tumour progression in mice (Karikoski
et al., 2014). SCARF1 has been shown to be upregulated in
the hepatic sinusoids and at the sites of tissue fibrosis in a
range of human CLDs (Patten et al., 2017a). Interestingly
SCARF1 is also expressed in well-differentiated HCC tumours,
whilst being downregulated in poorly differentiated HCC.
VAP-1 was previously shown to promote the recruitment of
Th2 lymphocytes rather than the Th1 subset in models of
concanavalin A-induced liver injury (Bonder et al., 2005).
VAP-1 is highly expressed in CLD (McNab et al., 1996; Weston
et al., 2015) and mediates recruitment both directly (Lalor
et al., 2002) and indirectly via its enzymatic activity, which
can upregulate expression of other adhesion molecules (Lalor
et al., 2007; Liaskou et al., 2011). VAP-1 is also expressed by
HSCs; blockade of both adhesive and enzymatic properties of
VAP-1 attenuates fibrosis, highlighting its therapeutic potential
(Weston et al., 2015). Another receptor which has recently
been highlighted in single-cell studies of the liver is PLVAP,
which is an endothelial-specific protein known to be involved in
leukocyte migration across lymphatics (Keuschnigg et al., 2009;
Rantakari et al., 2015). Whilst it has an instrumental role in foetal
liver-derived immune cell distribution (Rantakari et al., 2016), its
involvement in leukocyte recruitment within adult liver remains
to be explored. Nevertheless, PLVAP seems to be upregulated
during inflammatory states (Ramachandran et al., 2019;
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Su et al., 2020), and its re-emergence in the HCC
microenvironment (Wang et al., 2014) suggests a role in
pathogenesis which requires further investigation.
Inhibition of LSEC-cancer cell interactions represents an
additional strategy. Blockade of L-SIGN has shown promise
in reducing colon cancer metastasis in murine models (Zuo
et al., 2013; Na et al., 2017), whilst MR has been suggested as
a potential target for treating hepatic metastases and increasing
anti-tumour cytotoxicity (Arteta et al., 2010). Moreover, LSEC
Notch activation negatively regulates tumour cell adhesion
in a Wnt-independent manner, thus protecting against liver
metastasis (Wohlfeil et al., 2019). Selective modulation of
Notch activity has been proposed as a therapeutic option
in liver metastasis. The findings presented here suggest that
the targeting of LSEC receptors and LSEC-specific pathways
may be an attractive therapeutic strategy to modulate the
hepatic immune microenvironment. Which pathway to target
will be context-dependent; in CLD, the aim would be to
promote anti-inflammatory and pro-resolution conditions,
while in HCC, there will also be a need to drive an
immunogenic, anti-tumoural environment to support cancer
immunotherapy. Furthermore, targeting of cancer cell adhesion
to LSEC may offer a route to mitigate frequent metastasis
of solid tumours.
It is likely that the success of future LSEC treatments will
depend on the reliable delivery of agents to the sinusoidal
vascular bed in order to avoid systemic complications. This
has led to several approaches to directly target LSEC in pre-
clinical models (Poisson et al., 2017). For example, nanoparticles
developed to interact exclusively with LSEC have been trialled
in murine models of liver metastasis. Yu and colleagues
reported that LSEC are specifically targeted by alpha-melittin
nanoparticles (Yu et al., 2019), which increase numbers of
innate and adaptive immune cells in addition to promoting
T cell activation and NK cell maturation. Their ability to
prime the anti-tumour response prevents the formation of
metastasis. Moreover, melittin nanoparticles have a direct
cytotoxic effect on metastatic tumours. Mice treated with melittin
nanoparticles had significantly improved survival rates (Yu
et al., 2019). Using miRNA conjugated with chondroitin sulfate-
functionalised nanoparticles, Marquez and colleagues targeted
LSEC activation during angiogenesis. MiR-20a, a molecule
known to be downregulated in colorectal liver metastasis, was
replaced in LSEC of murine models of liver metastases (Marquez
et al., 2018). They found that targeting MiR-20a replacement
reduced LSEC recruitment into metastatic foci, and metastasis
size decreased by 80% following treatment. The development of
nanoparticles specifically targeting LSEC is of particular interest
as it enables a narrow therapeutic focus, potentially reducing
the risk of systemic toxicity. These approaches will hopefully
lead to the successful translation of LSEC-specific agents into
clinical trials.
CONCLUSION
LSEC play essential roles in physiology and homeostasis, with
their dysfunction preceding fibrogenesis that yields high risk of
carcinogenesis. Context-dependent LSEC signalling determines
the outcome of liver injury, either tissue regeneration or fibrosis,
providing strong support for LSEC as a target for fibrotic
disease. Furthermore, their active involvement in modulating the
immune and tumour microenvironment not only fosters primary
and secondary tumour development, but also offers promising
opportunities for therapeutic intervention.
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